| Literature DB >> 30630875 |
Ioannis Arsenakis1, Annelies Michiels1, Gabriele Schagemann2, Charles Oliver Gomez-Duran2, Filip Boyen3, Freddy Haesebrouck3, Dominiek G D Maes1.
Abstract
This study investigated Mycoplasma hyopneumoniae colonisation and lung lesions at slaughter in pigs from vaccinated (V) and non-vaccinated (NV) sows, in two herds (A and B). In each herd, two sow batches were V against M. hyopneumoniae with a commercial bacterin at six and three weeks before farrowing and two sow batches remained NV. From each sow batch, laryngeal swabs were collected from the litters of five primiparous sows at weaning and seven days post-weaning. All samples were tested for M. hyopneumoniae by nested PCR. In total, 488 piglets were sampled. At slaughter, the extent of Mycoplasma-like pneumonia lesions (lung lesion score (LLS)) was assessed. The colonisation rates with M. hyopneumoniae at weaning and seven days post-weaning were (V-A=14.2, NV-A=20.0 (P=0.225); V-B=0.9, NV-B=0.8 (P=0.948)) and (V-A=0.8, NV-A=7.0 (P=0.039); V-B=1.8, NV-B=2.5 (P=0.738)), respectively. The average LLS (in per cent) was V-A=15.5, NV-A=26.4 (P=0.021); V-B=9.7, NV-B=8.4 (P=0.541). In conclusion, in herd A, with a substantially higher level of piglet colonisation at weaning than herd B, offspring from V sows had a significantly lower colonisation rate seven days post-weaning and a significantly lower LLS at slaughter compared with the offspring of the NV sows. This implies that sow vaccination might be useful for control of M. hyopneumoniae infections, although significant results may not be achieved at all times (such as in herd B). © British Veterinary Association 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.Entities:
Keywords: Mycoplasma hyopneumoniae; lung lesions; pig colonization; sow vaccination
Mesh:
Year: 2019 PMID: 30630875 PMCID: PMC6589467 DOI: 10.1136/vr.104972
Source DB: PubMed Journal: Vet Rec ISSN: 0042-4900 Impact factor: 2.695
Herd description and health management practices
| Herd A | Herd B | |
| Number of sows | 400 | 600 |
| Breed of sows | Topigs 20 | DanBred |
| Breed of boars (sperm) | Belgian Piétrain | Belgian Piétrain |
| Vaccination of the sows | ||
| Atrophic rhinitis | Rhiniseng (Hipra) four weeks before farrowing | Porcilis AR-T (MSD) 4 weeks before farrowing |
| Parvovirus+ | Eryseng Parvo (Hipra) three weeks before breeding | Porcilis Ery-Parvo (MSD) 2 weeks before breeding |
| | Suiseng (Hipra) three weeks before farrowing | Porcilis coli (MSD) 3 weeks before farrowing |
| PRRS(V) | Ingelvac MLV (Boehringer Ingelheim) eight weeks before farrowing | Ingelvac MLV (Boehringer Ingelheim) applied twice/year |
| Vaccination of the quarantined gilts | ||
| PRRS(V) | Ingelvac MLV (Boehringer Ingelheim) four4 weeks after arrival | Ingelvac MLV (Boehringer Ingelheim) 2 weeks after arrival |
| PCV-2 | Ingelvac Circoflex (Boehringer Ingelheim) twice three weeks apart | Ingelvac Circoflex (Boehringer Ingelheim) twice 3 weeks apart |
| Atrophic rhinitis | Rhiniseng (Hipra) twice four weeks apart | Porcilis AR-T (MSD) twice 6 weeks apart |
| Management of the piglets | ||
| Days 2–4 | Amoxicillin (intramuscular) | Amoxicillin (IM) |
| Tail docking | Tail docking | |
| Castration | Castration | |
| Iron (Uniferon, Pharmacosmos) | Iron (Ferraject, Eurovet) | |
| Toltrazuril (Baycox, Bayer) | ||
| Vaccinations | At weaning | N/A |
| PRRS(V) | Ingelvac MLV (Boehringer Ingelheim) | N/A |
| Mhyo and PCV-2 | Ingelvac FLEXcombo (Boehringer Ingelheim) | N/A |
| Nursery (days 21–70) | ||
| Medication | Amoxicillin days 21–28 (IF) | Zinc oxide after weaning for 14 days at 2500 ppm (IF) |
| Facilities | One unit with four compartments | one unit with 12 compartments |
| 12 pens/compartment | 4 to 12 pens/compartment | |
| 40 pigs/pen (0.26 m2/pig) | 20 to 26 pigs/pen (0.24 to 0.27 m2/pig) | |
| Ventilation | Conventional mechanical ventilation | conventional mechanical ventilation |
| Fattening unit (days 70–220) | ||
| Medication | Flubendazole (days 70–75; IF), repeat every six weeks | Flubendazole (day 84 to 91 and day 110 to 117; IF) |
| Facilities | three fattening units, each having four compartments | two fattening units, each having 5 compartments |
| 14 or 16 pens/compartment | 8 or 10 pens/compartment | |
| 12 or 15 pigs/pen (0.75 m2/pig) | 10 or 15 pigs/pen (0.75 m2/pig) | |
| Ventilation | Mechanical door ventilation | natural ventilation |
IF, in-feed medication; N/A, non-applicable; PRRS(V), porcine reproductive and respiratory syndrome virus; PCV-2, porcine circovirus type 2.
Percentage and number (in parentheses) of sows with a M. hyopneumoniae nested-PCR-positive laryngeal swab
| a | b | c | d | P value | a–c (NV) | b–d (V) | P* value | |
| | 0.0 (0/5) | 0.0 (0/5) | 20.0 (1/5) | 0.0 (0/5) | 0.999 | 10.0 (1/10) | 0.0 (0/10) | 0.999 |
| a | b | c | d | P value | a–c (NV) | b–d (V) | P* value | |
| | 0.0 (0/5) | 40.0 (2/5) | 40.0 (2/5) | 20.0 (1/5) | 0.902 | 20.0 (2/10) | 30.0 (3/10) | 0.608 |
Vaccination status: NV (non-vaccinated sow batches) and V (vaccinated sow batches). The P value refers to the comparisons between the individual sow batches, and the P* value to the comparisons between the summaries of the NV (a–c) and V (b–d) batches. Differences between batches were not statistically significant (P>0.05).
Percentage and number (in parentheses) of piglets with a M. hyopneumoniae nested-PCR-positive laryngeal swab
| Age (weeks) | a | b | c | d | P value | a–c (NV) | b–d (V) | P* value | |
| 3 | 25.4 (15/59) | 14.9 (10/67) | 14.7 (9/61) | 13.3 (8/60) | 0.277 | 20.0 (24/120) | 14.2 (18/127) | 0.225 | |
| 4 | 12.5 (7/56) | 0.0 (0/66) | 1.7 (1/59) | 1.8 (1/57) | 0.088 | 7.0 (8/115)A | 0.8 (1/123)B | 0.039 | |
| Age (weeks) | a | b | c | d | P value | a–c (NV) | b–d (V) | P* value | |
| 4 | 0.0 (0/65) | 0.0 (0/57) | 1.6 (1/61) | 1.7 (1/58) | 0.997 | 0.8 (1/126) | 0.9 (1/115) | 0.948 | |
| 5 | 3.1 (2/64) | 1.8 (1/55) | 1.7 (1/58) | 1.8 (1/55) | 0.943 | 2.5 (3/122) | 1.8 (2/110) | 0.738 | |
Vaccination status: NV (pigs originating from non-vaccinated sow farrowing batches) and V (pigs originating from vaccinated sow farrowing batches). The P value refers to the comparisons between the individual farrowing batches, and the P* value to the comparisons between the summaries of the NV (a–c) and V (b–d) batches. Values with different superscripts within a row are significantly different (P<0.05).
Percentage and number (in parentheses) of pen-based oral fluid samples positive by nested-PCR for M. hyopneumoniae
| Age (weeks) | a | b | c | d | P value | a–c (NV) | b–d (V) | P* value | |
| 4 | 100.0 (2/2) | 0.0 (0/2) | 0.0 (0/2) | 0.0 (0/2) | N/A† | 50.0 (2/4) | 0.0 (0/4) | 0.429 | |
| Age (weeks) | a | b | c | d | P value | a–c (NV) | b–d (V) | P* value | |
| 5 | 0.0 (0/9) | 0.0 (0/7) | 25.0 (2/8) | 12.5 (1/8) | 0.941 | 11.8 (2/17) | 6.7 (1/15) | 1.000 | |
Vaccination status: NV (pens hosting pigs from non-vaccinated sow farrowing batches) and V (pens hosting pigs from vaccinated sow farrowing batches). The P value refers to the comparisons between the individual farrowing batches, and the P* value to the comparisons between the summaries of the NV (a–c) and V (b–d) batches. Differences between batches were not statistically significant (P>0.05).
†Non-applicable due to insufficient number of observations.
Percentage and number (in parentheses) of seropositive sows and pigs at 12–24 hours post-farrowing and at weaning, respectively, together with the inhibition percentages (IP)
| Herd A | ||||||||
| a | b | c | d | P value | a– c (NV) | b–d (V) | P* value | |
| Sows seropositive | 20.0 (1/5) | 80.0 (4/5) | 0.0 (0/5) | 100.0 (5/5) | 0.380 | 10.0 (1/10)A | 90.0 (9/10)B | 0.001 |
| Sows IP | 25.6AB | 77.5ABC | 26.8B | 94.4C | 0.005 | 26.2A | 86.0B | 0.000 |
| Pigs seropositive | 6.8 (4/59)A | 74.6 (50/67)B | 5.1 (3/59)C | 90.0 (54/60)D | 0.000 | 5.9 (7/118)A | 81.9 (104/127)B | 0.000 |
| Pigs IP | 15.6A | 68.1B | 29.0A | 79.6B | 0.000 | 22.3A | 73.2B | 0.000 |
| Herd B | ||||||||
| a | b | c | d | P value | a– c (NV) | b–d (V) | P* value | |
| Sows seropositive | 40.0 (2/5) | 80.0 (4/5) | 0.0 (0/4) | 80.0 (4/5) | 0.532 | 22.0 (2/9)A | 80.0 (8/10)B | 0.023 |
| Sows IP | 39.0AB | 56.4AB | 19.9A | 68.8B | 0.049 | 30.5A | 62.6B | 0.017 |
| Pigs seropositive | 42.2 (27/64)A | 66.7 (38/57)B | 3.3 (2/60)C | 77.6 (45/58)B | 0.000 | 23.4 (29/124)A | 72.2 (83/115)B | 0.000 |
| Pigs IP | 42.4A | 79.3B | 24.6C | 65.2D | 0.000 | 38.5A | 72.5B | 0.000 |
Vaccination status: NV (non-vaccinated sow batches and their pigs) and V (vaccinated sow batches and their pigs). The P value refers to the comparisons between the individual farrowing batches, and the P* value to the comparisons between the summaries of the NV (a–c) and V (b–d) batches. Values with different superscripts within a row are significantly different (P<0.05 and P*<0.05).
Percentage of pigs with Mycoplasma hyopneumoniae-like lung lesions (Mhyo) and fissures at slaughter, and lung lesion score (LLS; average ±SD)
| Herd A | ||||||||
| a ( | b ( | c ( | d ( | P value | a–c (NV; | b–d (V; | P* value | |
| Prevalence of | 95.7A | 65.2B | 60.0B | 47.6B | 0.038 | 77.1A | 56.8B | 0.045 |
| Prevalence of fissures | 33.3 | 17.4 | 0.0 | 0.0 | 0.676 | 16.3 | 9.1 | 0.360 |
| LLS | 29.4±19.1A | 14.9±16.7B | 23.6±28.6AB | 16.1±21.8B | 0.032 | 26.4±24.4A | 15.5±19.1B | 0.021 |
| Herd B | ||||||||
| a ( | b ( | c | d | P value | a–c (NV; | b–d (V; | P* value | |
| Prevalence of | 78.7 | 74.1 | N/A† | N/A† | N/A† | 78.7 | 74.1 | 0.649 |
| Prevalence of fissures | 46.8 | 37.9 | N/A† | N/A† | N/A† | 46.8 | 37.9 | 0.428 |
| LLS | 8.4±8.5 | 9.7±11.6 | N/A† | N/A† | N/A† | 8.4±8.5 | 9.7±11.6 | 0.541 |
Vaccination status: NV (pigs originating from non-vaccinated sow farrowing batches) and V (pigs originating from vaccinated sow farrowing batches). The P value refers to the comparisons between the individual farrowing batches, and the P* value to the comparisons between the summaries of the NV (a–c) and V (b–d) batches. Values with different superscripts within a row are significantly different (P<0.05 and P*<0.05).
†Non-applicable as pigs of batches c and d were slaughtered before the pre-arranged time and thus, no lung lesion evaluation was performed.